Roche said on Monday the U.S. Food and Drug administration granted priority review to its Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults.
A logo of Swiss pharmaceutical company Roche in Rotkreuz, Switzerland, April 12, 2012. REUTERS/Michael Buholzer/File Photosaid on Monday the U.S. Food and Drug administration granted priority review to its Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults.
"If approved, Actemra/RoActemra would be the first U.S. FDA-approved immunomodulator for the treatment of COVID-19 in hospitalised patients," Roche said in a statement, adding that more than 1 million people hospitalised with COVID-19 had been treated with Actemra/RoActemra worldwide since the beginning of the pandemic.Reporting by Silke Koltrowitz, Editing by Miranda MurraySign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
NPR Cookie Consent and Choices
Consulte Mais informação »
UPDATES: Tucson-area coronavirus developments, April 4: What we knowThe latest updates related to COVID-19 in Tucson and Southern Arizona.
Consulte Mais informação »
Dr. Nicole Saphier: Fauci, CDC ‘have not acknowledged natural immunity’Fox News medical contributor Dr. Nicole Saphier discusses COVID-19 natural immunity.
Consulte Mais informação »
Number of COVID-19 patients in hospitals reaches record low in USCOVID-19 hospitalization numbers have plunged to their lowest levels since the summer of 2020.
Consulte Mais informação »
Harris joins Biden in getting second COVID-19 booster shotVice President Kamala Harris has received her second booster for the COVID-19 vaccination.
Consulte Mais informação »
Covid-19: Six Covid-related deaths and 1,002 casesThe total number of deaths linked to Covid-19 in NI since the start of the pandemic is 3,335.
Consulte Mais informação »